Akums Drugs and Pharmaceuticals Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Akums Drugs and Pharmaceuticals Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Profit Cash Ratio: Over the last 3 years, every ₹100 of reported profit came with ₹364 of operating cash. Higher than 94% of Healthcare companies in India.
- Cash Cushion Ratio: Cash, after subtracting all debt, equals 14% of its market value (net cash). Higher than 94% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹364Over the last 3 years, every ₹100 of reported profit came with ₹364 of operating cash.
Higher than 94% of Healthcare companies in India.
Self-Funding Ratio
2.6×Over the last 3 years its own operating cash covered its investment spending (capex) 2.6 times.
Higher than 75% of Healthcare companies in India.
Cash Locked Ratio
₹20For every ₹100 of sales, ₹20 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹27 tied up three years earlier.
Less money tied up than 61% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 1/3Sales grew in 3 of the last 3 years; profit grew in 1 of 3.
Less steady than 68% of Healthcare companies in India.
Growth Efficiency Ratio
₹21Sales grew 22% in 3 years; of every extra ₹100 of sales, ₹21 became extra profit.
Higher than 64% of Healthcare companies in India.
Asset Productivity Ratio
+22% / +67%In 3 years sales changed by +22% while total assets changed by +67%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
11.0×Debt due within a year is covered 11.0 times by its yearly operating cash.
Higher than 78% of Healthcare companies in India.
Cash Cushion Ratio
+14%Cash, after subtracting all debt, equals 14% of its market value (net cash).
Higher than 94% of Healthcare companies in India.
Tangible Assets Ratio
100%Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 76% of Healthcare companies in India.
Tangible Net Worth Ratio
100%Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 76% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Akums Drugs and Pharmaceuticals Limited owes ₹0.39 for every ₹1 it owns. Net profit fell 25% in the year to Mar 2026, and grew 39% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
35.7Investors pay ₹35.7 for every ₹1 of Akums Drugs and Pharmaceuticals Limited's yearly profit, lower than 53% of Healthcare companies in India.
P/B ratio
3.14The share price is 3.14 times Akums Drugs and Pharmaceuticals Limited's book value per share, lower than 70% of Healthcare companies in India.
Market cap
₹10,414 CrThe total market value of all of Akums Drugs and Pharmaceuticals Limited's shares at today's price (share price × number of shares), larger than 64% of Healthcare companies in India. PosiCap size class: Meso Cap.
Net worth (book value)
₹3,313 CrWhat Akums Drugs and Pharmaceuticals Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹216.41Net worth divided by the number of shares. The share price of ₹680.20 is 3.1 times this, which is the P/B above.
Return on equity (ROE)
8.8%Akums Drugs and Pharmaceuticals Limited earned 8.8% on its shareholders' money over the last year, lower than 72% of Healthcare companies in India.
Owes vs Owns
0.39×Akums Drugs and Pharmaceuticals Limited owes ₹0.39 for every ₹1 it owns (low), higher than 56% of Healthcare companies in India.
Dividend yield
0.14%Akums Drugs and Pharmaceuticals Limited pays 0.14% of its share price as dividends a year, lower than 80% of dividend-paying Healthcare companies in India.
Revenue growth
+4%Revenue rose 4% in the year to Mar 2026, and grew 7% a year on average over 3 years.
Profit growth
-25%Net profit fell 25% in the year to Mar 2026, and grew 39% a year on average over 3 years.
Profit margin
6.0%Akums Drugs and Pharmaceuticals Limited keeps ₹6 of every ₹100 of revenue as net profit.
Cash quality
4.6×Cash from Akums Drugs and Pharmaceuticals Limited's business was 4.6× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
4.2×Akums Drugs and Pharmaceuticals Limited's operating profit covered its interest costs 4.2 times in the year to Mar 2026.
Cash vs debt
Net cashAkums Drugs and Pharmaceuticals Limited held ₹1,489 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Akums Drugs and Pharmaceuticals Limited's P/E ratio?
Investors pay ₹35.7 for every ₹1 of Akums Drugs and Pharmaceuticals Limited's yearly profit, lower than 53% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Akums Drugs and Pharmaceuticals Limited: ₹10,414 Cr ÷ ₹3,313 Cr (31 Mar 2026) = 3.1.
What is Akums Drugs and Pharmaceuticals Limited's return on equity?
Akums Drugs and Pharmaceuticals Limited earned 8.8% on its shareholders' money over the last year, lower than 72% of Healthcare companies in India.
How much does Akums Drugs and Pharmaceuticals Limited owe compared with what it owns?
Akums Drugs and Pharmaceuticals Limited owes ₹0.39 for every ₹1 it owns (low), higher than 56% of Healthcare companies in India.
Does Akums Drugs and Pharmaceuticals Limited pay a dividend?
Yes. Akums Drugs and Pharmaceuticals Limited pays 0.14% of its share price as dividends a year, lower than 80% of dividend-paying Healthcare companies in India.
Is Akums Drugs and Pharmaceuticals Limited's revenue growing?
Revenue rose 4% in the year to Mar 2026, and grew 7% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.